Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
The test is based on MDNA's Mitomic technology, which enables the isolation of mitochondrial DNA in circulation that may be used as biomarkers.
Following this agreement, LifeCodexx's PrenaTest is now available in more than 40 countries throughout Europe and the Middle East.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
This year, the vast majority of assays the Belgian company facilitates will be non-invasive prenatal testing, which it only started offering in 2013.
Participants of the National Society of Genetic Counselors annual education conference highlighted the need for consensus guidelines for screening potential gamete donors.
The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
Despite recent bills that argue the advent of NIPS will increase abortion, researchers say that there is not yet enough data.
Cystic fibrosis carrier status often did not impact family planning decisions and was sometimes perceived as a risk to unaffected family members.
The findings, published last week, have prompted Belgian medical genetics centers to routinely report maternal incidental findings from NIPT.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
Using absolute and relative gene expression analyses, researchers identified expression patterns associated with preeclampsia in dozens of placental tissue samples.
The study adds to a growing body of evidence suggesting that expanded carrier screening tests can better identify at-risk couples.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.
The company intends to use funds from a recent Series A financing round to hire new staff as well as develop new clinical tests and software products.
The project has recruited nearly half of the 1,000 families it plans to analyze and has completed the exome analysis for about 160.
ACMG said in a position statement that NIPS can replace conventional screening for Patau, Edwards, and Down syndrome in most women.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.